Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric enlicitide decanoate seamless Phase 2/3 study in heterozygous familial hypercholesterolemia
2024-519068-42-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised trial in heterozygous familial hypercholesterolemia (HeFH) comparing MK-0616 with Placebo to MK-0616 (2 arms). Primary endpoints: Maximum Plasma Concentration (Cmax) of Enlicitide, Area Under the Concentration-Time Curve from 0 to 24 Hours (AUC0-24) of Enlicitide and 3 more. Planned start Feb 2026; status: authorised.
02
Drugs
enlicitide
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2024-519068-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519068-42-00.